These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23656173)

  • 21. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
    Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.
    Woo PYM; Ho JWK; Ko NMW; Li RPT; Jian L; Chu ACH; Kwan MCL; Chan Y; Wong AKS; Wong HT; Chan KY; Kwok JCK
    BMC Neurol; 2020 Nov; 20(1):401. PubMed ID: 33143640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
    Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.
    Muresanu DF; Florian S; Hömberg V; Matula C; von Steinbüchel N; Vos PE; von Wild K; Birle C; Muresanu I; Slavoaca D; Rosu OV; Strilciuc S; Vester J
    Neurol Sci; 2020 May; 41(5):1171-1181. PubMed ID: 31897941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrolysin dose-dependently improves neurological outcome in rats after acute stroke: A prospective, randomized, blinded, and placebo-controlled study.
    Zhang L; Chopp M; Lu M; Zhang T; Winter S; Doppler E; Meier D; Chao L; Eapen A; Pabla P; Gang Zhang Z
    Int J Stroke; 2016 Apr; 11(3):347-55. PubMed ID: 26763925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
    Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
    Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.
    Alvarez XA; Sampedro C; Pérez P; Laredo M; Couceiro V; Hernández A; Figueroa J; Varela M; Arias D; Corzo L; Zas R; Lombardi V; Fernández-Novoa L; Pichel V; Cacabelos R; Windisch M; Aleixandre M; Moessler H
    Int Clin Psychopharmacol; 2003 Sep; 18(5):271-8. PubMed ID: 12920387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cerebrolysin in the treatment of brain injuries of moderate severity].
    Talypov AE; Myachin MY; Kuksova NS; Kordonsky AY
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):98-106. PubMed ID: 25591645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment.
    Cherrier MM; Matsumoto AM; Amory JK; Asthana S; Bremner W; Peskind ER; Raskind MA; Craft S
    Neurology; 2005 Jun; 64(12):2063-8. PubMed ID: 15985573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT).
    Zafonte RD; Bagiella E; Ansel BM; Novack TA; Friedewald WT; Hesdorffer DC; Timmons SD; Jallo J; Eisenberg H; Hart T; Ricker JH; Diaz-Arrastia R; Merchant RE; Temkin NR; Melton S; Dikmen SS
    JAMA; 2012 Nov; 308(19):1993-2000. PubMed ID: 23168823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study.
    Parle J; Roberts L; Wilson S; Pattison H; Roalfe A; Haque MS; Heath C; Sheppard M; Franklyn J; Hobbs FD
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3623-32. PubMed ID: 20501682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease.
    Wei ZH; He QB; Wang H; Su BH; Chen HZ
    J Neural Transm (Vienna); 2007; 114(5):629-34. PubMed ID: 17318304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke].
    Skvortsova VI; Stakhovskaia LV; Gubskiĭ LV; Shamalov NA; Tikhonova IV; Smychkov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; (Suppl 11):51-5. PubMed ID: 15559222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study.
    Wong GK; Zhu XL; Poon WS
    Acta Neurochir Suppl; 2005; 95():59-60. PubMed ID: 16463821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials.
    Guekht A; Vester J; Heiss WD; Gusev E; Hoemberg V; Rahlfs VW; Bajenaru O; Popescu BO; Doppler E; Winter S; Moessler H; Muresanu D
    Neurol Sci; 2017 Oct; 38(10):1761-1769. PubMed ID: 28707130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.
    Poon W; Matula C; Vos PE; Muresanu DF; von Steinbüchel N; von Wild K; Hömberg V; Wang E; Lee TMC; Strilciuc S; Vester JC
    Neurol Sci; 2020 Feb; 41(2):281-293. PubMed ID: 31494820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).
    Chen CL; Ikram K; Anqi Q; Yin WT; Chen A; Venketasubramanian N;
    Cerebrovasc Dis; 2013; 35 Suppl 1():23-9. PubMed ID: 23548916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.